SHENYANG, China and BEDFORD Mass., Nov. 17, 2019 /PRNewswire/ -- 3SBio Inc. ("3SBio") (HKEX:1530) and Verseau Therapeutics, Inc. ("Verseau") today announced the selection of VTX-0811, a monoclonal ...

Verseau Therapeutics Announces FDA Clearance of Investigational New Drug Application for VTX-0811, a PSGL-1 Monoclonal Antibody - Phase 1a/b Clinical Study of VTX-0811 in Solid Tumors Expected to ...

PSGL-1 is absent in t(8;21)+ AML cells. To identify adhesion molecules regulated by RE, we analyzed the adhesion molecule expression pattern of Kasumi-1 cells compared with human CD34+ cells ...

PSGL-1 plays a key role in regulating late-stage, chronically activated T-cells. ALTB-268 helps to restore the immune system to a state of balance without interfering with cell migration.

Yuntao Wu, Professor, Molecular and Microbiology, School of Systems Biology, College of Science, is studying the structure of dicameric repeats (DR) of PSGL-1, a host protein that inhibits HIV ...

"PSGL-1 inhibitors could provide another tool in the arsenal against cancer, and benefit the many patients who don't respond to the currently available checkpoint inhibitors." ...

PSGL-1 VNTR polymorfism was related with site of thrombosis. AB and AC types were more frequent in patients with CVC-R and other vein thrombosis (p=0.02). Besides heterozygosity (AB+AC) relationship ...

SHENYANG, China and BEDFORD Mass., Nov. 17, 2019 /PRNewswire/ -- 3SBio Inc. ('3SBio') (HKEX:1530) and Verseau Therapeutics, Inc. ('Verseau') today ...

By targeting PSGL-1, an adhesion molecule that is highly expressed on tumor-associated macrophages across most tumor types, VTX-0811 reprograms macrophages to a pro-inflammatory state, activates T ...

PSGL-1, a novel target for immunotherapy, can induce macrophage reprogramming and activate a coordinated anti-tumor inflammatory response SHENYANG, China and BEDFORD Mass., Nov. 18, 2019 ...